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TCF1þ hepatitis C virus-speciﬁc CD8þ T cells are
maintained after cessation of chronic antigen
stimulation
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Differentiation and fate of virus-speciﬁc CD8þ T cells after cessation of chronic antigen
stimulation is unclear. Here we show that a TCF1þCD127þPD1þ hepatitis C virus (HCV)-
speciﬁc CD8þ T-cell subset exists in chronically infected patients with phenotypic features of
T-cell exhaustion and memory, both before and after treatment with direct acting antiviral
(DAA) agents. This subset is maintained during, and for a long duration after, HCV
elimination. After antigen re-challenge the less differentiated TCF1þCD127þPD1þ popula-
tion expands, which is accompanied by emergence of terminally exhausted TCF1-CD127-
PD1hi HCV-speciﬁc CD8þ T cells. These results suggest the TCF1þCD127þPD1þ HCV-
speciﬁc CD8þ T-cell subset has memory-like characteristics, including antigen-independent
survival and recall proliferation. We thus provide evidence for the establishment of
memory-like virus-speciﬁc CD8þ T cells in a clinically relevant setting of chronic viral
infection and we uncover their fate after cessation of chronic antigen stimulation, implicating
a potential strategy for antiviral immunotherapy.
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H
uman chronic viral infections with hepatitis C virus
(HCV), hepatitis B virus (HBV) and human
immunodeﬁciency virus (HIV) are a major global health
problem. A rheostat that determines control versus active
persistence of these viral infections is the virus-speciﬁc
CD8þ T-cell response1,2. Virus-speciﬁc CD8þ T cells are
polyfunctional in controlled infection, whereas virus-speciﬁc
CD8þ T-cell function is compromised in actively persisting
infection. One important mechanism underlying impaired virus-
speciﬁc CD8þ T-cell responses in human chronic viral infection
is the progressive loss of effector functions, a phenomenon called
T-cell exhaustion3–5. Thus, immunotherapeutic strategies that
interfere with virus-speciﬁc CD8þ T-cell exhaustion and
consequently boost polyfunctional CD8þ T-cell responses are
considered to be promising approaches to combat or prevent
chronic viral infections in humans.
Major advances in the understanding of CD8þ T-cell
exhaustion during chronic viral infection in general have been
made using the lymphocytic choriomeningitis virus (LCMV)
mouse model. In particular, exhausted CD8þ T cells can be
deﬁned by a reduced cytokine production, an impaired
proliferative capacity, the expression of multiple co-inhibitory
molecules, the up-regulation of ectonucleotidase CD39 and an
altered global transcriptional program and epigenetic proﬁle6–9.
Several of these characteristics have also been reported for
exhausted virus-speciﬁc CD8þ T cells in human chronic
infections including functional impairment, co-expression of
inhibitory receptors and the increased expression of CD39 and
the transcription factor Eomes10–14. Importantly, in chronic
LCMV infection, exhausted virus epitope-speciﬁc CD8þ T-cell
populations are not homogeneous. Two subsets of exhausted
LCMV epitope-speciﬁc CD8þ T cells are deﬁned by differential
levels of the inhibitory receptor PD1 and the two transcription
factors Tbet and Eomes15. TbethiEomesdimPD1int LCMV-speciﬁc
CD8þ T cells are progenitor cells that can give rise to terminally
exhausted TbetdimEomeshiPD1hi cells. Both progenitor and
terminal subsets of exhausted LCMV epitope-speciﬁc CD8þ
T cells are required to sustain viral control during viral
persistence15. With respect to chronic infections in humans,
however, our knowledge about subsets, differentiation and
maintenance of virus-speciﬁc CD8þ T cells is limited and
efﬁcient immunotherapeutic approaches are required.
Although, the mechanisms responsible for CD8þ T-cell
exhaustion are not completely understood, an important feature
seems to be prolonged and continuous exposure to antigen
and, consequently, progressive terminal differentiation16–18.
Additional factors, including lack of CD4þ T-cell help,
immunosuppressive cytokines and instructive signals directly
from inhibitory receptors also contribute to T-cell
exhaustion6,19,20. Remarkably, blockade of the PD1/PDL1
inhibitory pathway leads to functional restoration of exhausted
virus-speciﬁc CD8þ T cells21–23. Therefore, despite ongoing
antigen recognition and consequently progressive terminal
differentiation, functional T-cell exhaustion, in principle, is
reversible. Importantly, only a distinct sub-population of less
differentiated PD1þ virus-speciﬁc CD8þ T cells is rescued by
blockade of the PD1/PDL1 pathway in chronic LCMV infection,
whereas terminally exhausted subsets do not respond well24.
PD1þ LCMV-speciﬁc CD8þ T cells that provide the
proliferative burst after PD1/PDL1 pathway blockade are
characterized by CXCR5 and TCF1 expression and by a unique
gene signature25–28. Interestingly, this LCMV-speciﬁc CD8þ
T-cell population possesses self-renewal capacity, gives rise to
terminally exhausted effector subsets and therefore sustains the
virus-speciﬁc CD8þ T-cell pool during antigen persistence.
Furthermore, the LCMV-speciﬁc TCF1þCD8þ T-cell subset
readily expands after transfer into naive mice and upon re-
challenge with LCMV, suggesting memory-like characteristics27.
The fate of exhausted virus-speciﬁc CD8þ T cells after
cessation of chronic antigen stimulation in a previously
persistently infected organism has not been deﬁned - neither in
mice nor in humans. In the LCMV mouse model, drugs that
efﬁciently eliminate the virus are not available. The same holds
true for human persistent infections with the exception of
IFNa-based therapies for chronic viral hepatitis. IFNa has a
known immunomodulatory effect during therapy, rendering
studies of immune function difﬁcult to interpret29,30. The fate
of exhausted virus-speciﬁc CD8þ T cells after removal of
persistent antigen, however, is of central clinical relevance since it
has implications for protection from re-infection after antigen
elimination. By approval of direct acting antiviral (DAA) agents
for HCV therapy that are highly efﬁcient at viral elimination this
important question can now be addressed for the ﬁrst time. Here
we take advantage of a well-deﬁned cohort of chronically HCV-
infected patients who have been treated successfully with DAAs.
We comprehensively study virus-speciﬁc CD8þ T-cell responses
during and after chronic antigen exposure at a single-cell level.
Importantly, we identify a CD127þPD1þ population of
exhausted HCV epitope-speciﬁc CD8þ T cells during antigen
persistence that is maintained long-term after cessation of chronic
antigen stimulation. This CD127þPD1þ subset is further
characterized by the expression of TCF1 and BCL2 and thus
shows phenotypic features of both T-cell memory and
exhaustion. When re-stimulated in vitro the TCF1þCD127þ
PD1þ subset contains the proliferative capacity of the
HCV-speciﬁc CD8þ T-cell population both during and after
antigen persistence. Moreover, this subset expands in response to
viral relapse in vivo. In sum, TCF1 deﬁnes a CD127þPD1þ
subset of HCV-speciﬁc CD8þ T cells that exhibits memory-like
characteristics and therefore appear to be a promising target to
boost HCV-speciﬁc CD8þ T cell responses for immuno-
therapeutic interventions and protection from re-infection.
Results
T-cell heterogeneity during persistent antigen recognition. In
chronic HCV infection, the expression levels of the inhibitory
receptor PD1 and the IL7R a-chain, CD127, have been proposed
to discriminate between virus-speciﬁc CD8þ T cells that are
exhausted due to persistent recognition of autologous viral
epitopes and virus-speciﬁc CD8þ T cells that do not recognize
autologous viral epitopes due to the emergence of viral escape
mutations10,31. Indeed, HCV-speciﬁc CD8þ T-cell populations
that predominantly express CD127 indicate the presence of viral
sequence variations in the corresponding viral epitope. In
contrast, in the absence of viral sequence variations and thus
ongoing antigen triggering, HCV-speciﬁc CD8þ T cells exhibit
high expression of PD1, co-expression of additional inhibitory
receptors and low proliferative capacity, suggesting exhaustion
of this T-cell population. However, whether an exhausted
HCV-speciﬁc CD8þ T-cell population targeting a single
epitope is a homogeneous population has not been analysed
previously. To address this question we performed co-expression
analyses of PD1 and CD127 on single HCV epitope-speciﬁc
CD8þ T cells and applied the peptide/MHCI tetramer-
associated magnetic bead enrichment technique to allow high
sensitivity HCV epitope-speciﬁc CD8þ T-cell characterization
(Supplementary Fig. 1). Peptide/MHCI tetramers speciﬁc for
three well-described HLA-A*02-restricted epitopes (NS31073;
NS31406; NS52594) were utilized and naive HCV epitope-speciﬁc
CD8þ T cells were excluded from the analyses (Supplementary
Fig. 2). CD127/PD1 co-expression of 24 HCV epitope-speciﬁc
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CD8þ T-cell populations derived from 19 chronically
HCV-infected patients that target autologous viral epitopes
(Table 1) is depicted in Fig. 1a with a representative dot plot
shown on the left. Interestingly, most HCV epitope-speciﬁc
CD8þ T-cell populations did not display a homogenous but
rather a heterogeneous phenotype that included CD127þPD1þ
(Mdn: 45.7%; IQR: 22.0-65.7%), CD127-PD1lo (Mdn: 17.7; IQR:
6.6-25.7%) and CD127-PD1hi (Mdn: 17.1; IQR: 11.0-51.1%)
subsets, rendering a subset of the HCV epitope-speciﬁc CD8þ
T cells responsive to the T-cell maintenance factor IL-7.
To determine whether this heterogeneous phenotype of HCV
epitope-speciﬁc CD8þ T cells is linked to persistent antigen
recognition, we next analysed CD127 and PD1 co-expression on
5 HCV epitope-speciﬁc CD8þ T-cell populations derived from 5
chronically HCV-infected patients that did not recognize the
autologous viral epitope due to the presence of viral escape
mutations (Table 1). As shown in Fig. 1b, HCV epitope-speciﬁc
CD8þ T cells that target variant epitopes and are thus
not triggered by ongoing antigen recognition do not show
strong heterogeneity but rather consist of a predominantly
CD127þPD1þ population (Mdn: 82.7%; IQR: 73.8-93.1%).
These results clearly demonstrate that persistent antigen
recognition induces heterogeneity of a single HCV epitope-
speciﬁc CD8þ T-cell population and more speciﬁcally the
occurrence of a CD127-PD1hi HCV epitope-speciﬁc CD8þ
T-cell subset.
Table 1 | Patient characteristics.
Pt D Cohort Treatment Outcome gt NS31073 NS31406 NS52594 VL Age Sex CIR
1 cHCV DAA Ledipasvir/Sofosbuvir 8 wk SVR 1a ------V--- 0.15 47 f no
2 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- 0.26 60 m no
3 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- ---------- 1.06 52 m no
4 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a ------V--- 3.20 66 f no
5 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- ---------- 0.63 59 f no
6 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a ---------- ---------- 0.68 64 f no
7 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- ---------- 2.96 50 m no
8 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- ND 49 m no
9 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- ---------- 15.0 58 m no
10 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- 0.29 59 m no
11 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1a --------- 1.03 47 m no
12 cHCV DAA Ledipasvir/Sofosbuvir/Ribavirin 12 wk SVR 1a ------V--- 0.04 73 f no
13 cHCV DAA Ledipasvir/Sofosbuvir/Ribavirin 12 wk;
untreated after relapse
RELAPSE 1a --------- ND 62 m yes
14 cHCV DAA Ledipasvir/Sofosbuvir 8 wk SVR 1b -I------- 0.70 49 m no
15 cHCV DAA Ledipasvir/Sofosbuvir 8 wk SVR 1b --------- 0.30 60 f no
16 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1b --------- 5.30 78 f no
17 cHCV DAA Ledipasvir/Sofosbuvir 12 wk SVR 1b --------- 1.00 63 f no
18 cHCV DAA Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir 12 wk SVR 1b -I------- 1.23 29 m no
19 cHCV DAA Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir/
Ribavirin 12 wk
SVR 1b --------- 0.04 66 f no
20 cHCV DAA Ledipasvir/Sofosbuvir/Ribavirin 12 wk SVR 1b -I------- 0.61 58 f no
21 cHCV untreated - - 1a --------- 1.36 41 m no
22 cHCV untreated - - 1a --------- 4.59 51 m no
23 cHCV untreated - - 1a ---------- 0.41 55 f no
1 cHCV ESC Ledipasvir/Sofosbuvir 8 wk SVR 1a --------A 0.15 47 f no
4 cHCV ESC Ledipasvir/Sofosbuvir 12 wk SVR 1a --------A 3.2 66 f no
12 cHCV ESC Ledipasvir/Sofosbuvir/Ribavirin12 wk SVR 1a --------A 0.04 73 f no
24 cHCV ESC Ledipasvir/Sofosbuvir 12 wk SVR 1b --S------ 2.46 56 f no
25 cHCV ESC - SVR 1b -------SA 0.04 57 m no
Pt D Cohort Approx. time after primary HCV infection Age Sex CIR
26 SpR SpR 22 years 43 m no
27 SpR SpR unknown 39 f no
28 SpR SpR unknown 25 m no
29 SpR SpR unknown 67 f no
30 SpR SpR unknown 38 f no
31 SpR SpR unknown 23 m no
32 SpR SpR unknown 54 m no
33 SpR SpR unknown 57 f no
34 SpR SpR unknown 42 m no
35 SpR SpR 12 years 39 f no
36 SpR SpR 19 years 37 m no
37 SpR SpR unknown 38 m no
38 SpR SpR unknown 60 f no
39 SpR SpR unknown 54 f no
40 SpR SpR 13 years 33 m no
CIR, cirrhosis; D, diagnosis; f, female; gt, HCV genotype; m, male; ND, not deﬁned; Pt, patient; SVR, sustained virological response; VL, baseline viral load (IUml 1 106); wk, week.
Patient characteristics are depicted. Listed are chronically HCV-infected patients (cHCV) with and without DAA treatment (DAA or untreated) and spontaneous HCV resolvers (SpR). In column NS31073,
NS31406 and NS52594 the viral sequence for each analysed CD8
þ T-cell epitope during chronic HCV infection is shown: (-) indicates a sequence position that corresponds to wild type viral sequence,
capital letters show amino acid substitutions varying from wild type sequence. Patients with analysed HCV epitope-speciﬁc CD8þ Tcells that do not recognize viral antigen due to viral escape mutation
in their corresponding epitope are listed in ESC (viral escape) cohort. If known, the approximate time after primary HCV inection of a SpR patient is indicated.
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TCF1 deﬁnes a memory-like HCV-speciﬁc CD8þ T-cell subset.
Next we set out to deﬁne the molecular signatures of the different
CD127/PD1 subsets of HCV epitope-speciﬁc CD8þ T cells.
CD127-PD1hi HCV epitope-speciﬁc CD8þ T cells exhibited
increased levels of the inhibitory receptors 2B4 and TIGIT
(Fig. 2a), expressed the ectonucleotidase CD39 (Fig. 2b) and
displayed high levels of the transcription factor Eomes (Fig. 2c).
Thus, this subset displayed typical features of terminal T-cell
exhaustion. In contrast, CD127þPD1þ HCV epitope-speciﬁc
CD8þ T cells expressed low levels of inhibitory receptors, CD39
and Eomes (Fig. 2a–c). Of note, all HCV-speciﬁc CD8þ T cells
are T-betdim (Supplementary Fig. 3). To further address the
differentiation stage of the particular CD127/PD1 subsets,
we stained for the effector cell molecule perforin and the
transcription factor TCF1 that is required for the differentiation
and persistence of memory CD8þ T cells32–34. While 14.9%
(IQR: 5.6–47.4%) of CD127-PD1hi HCV epitope-speciﬁc CD8þ
T cells expressed perforin, CD127þPD1þ subsets almost
completely lacked perforin expression (Fig. 2d). On the other
hand, CD127þPD1þ HCV epitope-speciﬁc CD8þ T cells
harboured the highest proportion of TCF1 expressing cells
(Mdn: 80.0%; IQR: 66.5–91.0%) compared to CD127-PD1lo
(Mdn: 38.3%; IQR: 19.7–60.8%) and CD127-PD1hi (Mdn:
26.2%; IQR: 16.3–33.7%) subsets (Fig. 2e). Of note, we did not
observe expression of CXCR5 on TCF1þ HCV epitope-speciﬁc
CD8þ T cells (Supplementary Fig. 4). Altogether, these data
suggest that CD127þPD1þ HCV epitope-speciﬁc CD8þ T cells
represent less differentiated memory-like cells while CD127-
PD1hi cells deﬁne terminally exhausted effector subsets of HCV
epitope-speciﬁc CD8þ T cells. As shown in Fig. 2f, this
hypothesis was further supported by the ﬁnding, that similar to
memory CD8þ T cells CD127þPD1þ HCV epitope-speciﬁc
CD8þ T cells expressed the anti-apoptotic molecule BCL2 to a
great extent (Mdn: 78.8%; IQR: 60.7–91.1%) whereas CD127-
PD1hi subsets showed minor expression of BCL2 (Mdn: 20.2%;
IQR: 6.8-33.2%). The low expression of BCL2 in this terminal
differentiated sub-population was accompanied by high caspase-8
activity (Fig. 2g) suggesting depletion of the CD127-PD1hi sub-
population by apoptosis. Interestingly, CD127-PD1hi HCV
epitope-speciﬁc CD8þ T cells are positive for CD122 (Mdn:
84.6%; IQR: 69.1-90.3%; Supplementary Fig. 5) rendering these
cells susceptible for IL-15-mediated bystander proliferation as has
been reported for effector and effector-memory CD8þ T cells.
Memory-like T cells are maintained antigen-independently.
Antigen-independent survival is a hallmark of memory CD8þ
T cells in resolved infections. In the LCMV mouse model of
chronic infection, antigen-independent maintenance and conse-
quently memory potential of exhausted virus-speciﬁc CD8þ
T cells has also been demonstrated after transfer in naive mice18,35.
However, in humans, very little is known about memory potential
including survival characteristics of exhausted virus-speciﬁc CD8þ
T-cell subsets. To assess whether CD127/PD1 subsets reveal
differences in survival depending on the presence of antigen we
longitudinally analysed HCV epitope-speciﬁc CD8þ T cells of 22
chronically HCV-infected patients after initiation of DAA therapy
(Table 1 and Supplementary Fig. 6). As shown in Fig. 3a and
Table 1, DAA therapy led to a rapid decline of viremia early after
therapy initiation and to a sustained virological response (SVR),
deﬁned as undetectable HCV RNA 12 weeks post treatment in all
but one treated patients. The single patient with viral relapse was
excluded from the SVR cohort (n¼ 21) and analysed separately.
Inhibition of viral replication and most likely removal of viral
antigen led to signiﬁcant dynamic changes in the CD127/PD1
subset distribution within single HCV epitope-speciﬁc CD8þ
T-cell populations (Fig. 3b). As shown in Fig. 3c–e and
Supplementary Fig. 7b, we found a dramatic decrease in the
frequency of CD127-PD1hi HCV epitope-speciﬁc CD8þ T cells
(Fig. 3c) with a concomitant increase in the frequency of the
CD127þPD1þ subset (Fig. 3d and Supplementary Fig. 8) while
the CD127-PD1lo T-cell population remained rather unchanged
(Fig. 3e). Of note, we did not observe changes in the overall
frequency of HCV epitope-speciﬁc CD8þ T cells (Supplementary
Fig. 7a). In agreement with our ﬁnding that the CD127-PD1hi
subset represents terminally exhausted T cells, we also observed a
signiﬁcant decrease in the frequencies of HCV epitope-speciﬁc
CD8þ T cells that highly express CD39 (Fig. 3f) and Eomes
(Fig. 3g) after initiation of DAA therapy and consequent cessation
of chronic antigen stimulation. In addition, initiation of DAA
therapy led to a signiﬁcant relative increase of TCF1þ HCV
epitope-speciﬁc CD8þ T cells (Fig. 3h,i) that can be ascribed to the
increased frequency of CD127þPD1þ HCV epitope-speciﬁc
CD8þ T cells since TCF1 expression remained stable within the
CD127þPD1þ subset (Fig. 3h,j and Supplementary Fig. 9). To
conﬁrm that the dynamic changes of HCV epitope-speciﬁc CD8þ
T cells induced by DAA therapy are indeed due to the cessation of
chronic antigen stimulation we additionally analysed HLA-
A*0201-restricted Flu M158 - and CMV pp65495-speciﬁc CD8þ
T cells derived from DAA-treated HCV-infected patients
(Supplementary Table 1). Importantly, these virus-speciﬁc CD8þ
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Figure 1 | Persistent antigen recognition drives heterogeneity of
HCV-speciﬁc CD8þ T cells. (a) CD127/PD1 co-expression analysis of 24
HCV epitope-speciﬁc CD8þ T-cell populations derived from 19 chronically
HCV-infected patients targeting autologous viral epitopes. Subset
deﬁnition, speciﬁcally CD127þPD1þ , CD127-PD1lo and CD127-PD1hi cells,
is depicted in the representative ﬂow cytometry dot plot on the left (red:
HCV epitope-speciﬁc CD8þ T cells; grey: corresponding bulk CD8þ
T cells of the appropriate patient). (b) Analysis of CD127/PD1
co-expression of ﬁve HCV epitope-speciﬁc CD8þ T-cell populations from
ﬁve chronically HCV-infected patients that do not recognize viral antigen
due to viral escape mutations. Representative dot plot on the left shows
HCV epitope-speciﬁc (red) and bulk (grey) CD8þ T cells. Bar charts show
the median value with interquartile range. Friedman and Dunn’s multiple
comparison tests were applied for paired statistical analyses. (*Po0.05)
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T cells remained phenotypically stable (Supplementary Fig. 10a–e)
clearly indicating that the observed changes in HCV epitope-
speciﬁc CD8þ T cells are linked to cessation of chronic antigen
stimulation rather than abrogation of the inﬂammatory milieu. To
further conﬁrm antigen-dependency and to exclude DAA-speciﬁc
effects, we analysed HCV epitope-speciﬁc CD8þ T-cell responses
of patients successfully treated with IFNa-based therapy. Due to
the immunomodulatory effects of IFNa-based therapy, we
comapred patient samples acquired before therapy and at a late
time point following IFNa administration. The observed changes
in CD127/PD1, CD39, Eomes and TCF1 expression of HCV
epitope-speciﬁc CD8þ T cells based on IFNa therapy
(Supplementary Table 2 and Supplementary Fig. 10f–k) were
similar to the ones observed with IFNa-free DAA therapy. These
results conﬁrm the impact of persistent antigen on virus-speciﬁc
CD8þ T cells and the presence of memory-like HCV epitope-
speciﬁc CD8þ T cells that are maintained after antigen
elimination.
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Memory-like and conventional memory T cells differ. Next,
we asked whether the HCV epitope-speciﬁc CD8þ T-cell
populations that are maintained after spontaneous or
DAA-mediated viral clearance show a similar phenotype
(Table 1). As shown in Fig. 4a-d, the CD127/PD1 subset
distribution of HCV epitope-speciﬁc CD8þ T cells differed
between the two cohorts. Speciﬁcally, HCV epitope-speciﬁc
CD8þ T cells derived from donors with spontaneous HCV
elimination contained a CD127þPD1- subset (Mdn: 33.1%; IQR:
19.8-43.9%) that was almost completely absent in HCV epitope-
speciﬁc CD8þ T cells from DAA-treated donors (Fig. 4c). This
difference in CD127/PD1 subset distribution was accompanied
on a transcriptional level by a lower expression of Eomes (Fig. 4e)
and a higher expression of TCF1 (Fig. 4f). Taken together, these
results clearly show phenotypical differences between memory-
like HCV epitope-speciﬁc CD8þ T cells that are maintained after
DAA-mediated viral clearance and conventional memory HCV
epitope-speciﬁc CD8þ T cells that persist after spontaneous viral
clearance. Hence, HCV-speciﬁc CD8þ T-cell differentiation
varies in chronic and acute resolved infection, although persisting
memory and short-lived effector subsets are established in both
differentiation programs.
Impaired T-cell effector function after antigen elimination. In
chronic infection, HCV-speciﬁc CD8þ T cells display impaired
cytokine secretion and consequently diminished antiviral efﬁcacy
due to their functional exhaustion1,36,37. This is in contrast to
memory HCV-speciﬁc CD8þ T cells after spontaneous virus
elimination that exhibit potent antiviral efﬁcacy1,36. To assess the
capability of memory-like HCV epitope-speciﬁc CD8þ T cells
that are maintained after DAA-mediated HCV elimination to
produce cytokines, we performed a combined peptide/MHCI
tetramer and intracellular cytokine-staining assay. As shown in
Fig. 5a,b, peptide stimulation did not induce ex vivo production of
IFNg or TNF by HCV epitope-speciﬁc CD8þ T cells that
persisted following DAA therapy.
In contrast, FLU epitope-speciﬁc CD8þ T cells were able to
produce IFNg and TNF after FLU M158 peptide stimulation
(Fig. 5b and Supplementary Fig. 11). Of note, we also could not
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detect ex vivo cytokine production after peptide stimulation of
HCV epitope-speciﬁc CD8þ T cells derived from donors that
spontaneously eliminated HCV possibly reﬂecting reduced assay
sensitivity due to the combination of peptide/MHCI tetramer
staining and peptide stimulation (Fig. 5b and Supplementary
Fig. 12).
Next, we determined the capability of HCV epitope-speciﬁc
CD8þ T cells to produce cytokines after HCV peptide-speciﬁc
expansion of CD8þ T cells. Importantly, we could detect
cytokine production by HCV epitope-speciﬁc CD8þ T cells
after a 14-day expansion (Fig. 5c,d). Interestingly, peptide-
expanded HCV-speciﬁc CD8þ T cells derived from donors at the
end of DAA therapy exhibited increased IFNg production (Mdn:
1.13%; IQR: 0.23–1.86%) compared to therapy baseline (Mdn:
0.14%; IQR: 0–0.53%) (Fig. 5d). To dissect cytokine production
from proliferation, we analysed TNF production by IFNgþ
expanded HCV epitope-speciﬁc CD8þ T cells (Fig. 5e). Strik-
ingly, TNF production was elevated among IFNgþ HCV
epitope-speciﬁc CD8þ T cells after DAA therapy (Baseline:
Mdn: 2.88%; IQR: 0.39–8.52%; end of therapy (EOT): Mdn:
6.39%; IQR: 4.05–23.22%). However, TNF production was still
decreased compared to IFNgþ HCV epitope-speciﬁc CD8þ
T cells present after spontaneous viral elimination (Mdn: 32.10%;
IQR: 16.15–54.32%) suggesting reduced poly-functionality of
HCV epitope-speciﬁc CD8þ T cells present after DAA-mediated
viral elimination as compared to spontaneous HCV resolution.
TCF1 expression correlates with proliferative capacity.
A further aspect of T-cell functionality is the proliferative capacity
upon antigen encounter. Therefore, we tested HCV epitope-
speciﬁc CD8þ T-cell proliferation before and after DAA-medi-
ated HCV elimination. For this, we determined the fold expan-
sion of HCV epitope-speciﬁc CD8þ T cells after 14-day HCV
peptide-speciﬁc expansion assays. As previously shown38, the
majority of analysed patients showed a signiﬁcant increase in the
expansion of HCV epitope-speciﬁc CD8þ T cells after antigen
removal (Fig. 6a). However, the proliferative capacity of HCV
epitope-speciﬁc CD8þ T cells obtained at the end of DAA
treatment (expansion factor: Mdn: 0.63; IQR: 0.13–1.16) was
reduced compared to HCV epitope-speciﬁc CD8þ T cells
obtained from patients with spontaneous viral clearance
(expansion factor: Mdn: 2.32; IQR: 1.63–2.87). We next
addressed the question whether the abundance of
CD127þPD1þ HCV epitope-speciﬁc CD8þ T cells accounts
for the proliferative potential of the HCV epitope-speciﬁc CD8þ
T-cell population. Indeed, the proliferative capacity of HCV
epitope-speciﬁc CD8þ T-cell populations correlated with the
abundance of CD127þPD1þ and particularly with that of
TCF1þ HCV epitope-speciﬁc CD8þ T cells (Fig. 6b,c). These
results suggest that TCF1 deﬁnes the proliferative capacity of
CD127þPD1þ virus-speciﬁc CD8þ T cells during and after
chronic antigen stimulation.
Memory-like T cells provide recall response. We had the single
opportunity to analyse the re-expansion capacity of memory-like
TCF1þCD127þPD1þ HCV epitope-speciﬁc CD8þ T cells
in vivo, since one DAA-treated patient presented with viral
relapse at the 12-week follow-up (FU12) visit (Table 1 and
Fig. 7a). Importantly, as shown in Fig. 7b, viral relapse and thus
antigen re-exposure led to a vigorous expansion of HCV NS31073-
speciﬁc CD8þ T cells that was accompanied with CD127/PD1
subset re-distribution (Fig. 7c and Supplementary Fig. 13) and
concomitant phenotypic changes (Fig. 7d–f). More speciﬁcally,
viral relapse led to a 2.9-fold increase of CD127-PD1hi HCV
NS31073-speciﬁc T cells that were roughly maintained at a 1-year
follow-up visit (2.4-fold increase relative to EOT). In concert with
this, expression of CD39 and Eomes increased (Fig. 7d,e) while
expression of TCF1 decreased (Fig. 7f) indicative of the re-gen-
eration of terminally exhausted effector subsets. These results,
therefore, clearly suggest that memory-like TCF1þCD127þ
PD1þ HCV epitope-speciﬁc CD8þ T cells are able to re-expand
efﬁciently in response to antigen re-exposure and can give
rise to terminally exhausted effector subsets characterized
by TCF1-CD127-PD1hi expression in the context of viral relapse.
Discussion
In this study, we analysed circulating HCV epitope-speciﬁc
CD8þ T cells in a clinically relevant model. We could deﬁne key
characteristics of distinct heterogeneous HCV epitope-speciﬁc
CD8þ T-cell subsets during antigen persistence and elimination
in the peripheral blood. Based on CD127/PD1 co-expression
analyses, we found that CD127þPD1þ , CD127-PD1lo and
CD127-PD1hi subsets contribute to the HCV epitope-speciﬁc
CD8þ T-cell pool during antigen persistence. Intriguingly,
however, only the CD127þPD1þ HCV epitope-speciﬁc CD8þ
T-cell subset is maintained after DAA-mediated HCV clearance
indicating memory-like survival characteristics. The CD127þ
PD1þ HCV-speciﬁc CD8þ T-cell subset is characterized by a
high expression of the transcription factor TCF1 that has been
shown to be essential for the establishment and persistence of
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CD8þ T-cell responses25,27,32,33,39. More speciﬁcally, it has been
reported that TCF1 deﬁnes the proliferative capacity of virus-
speciﬁc CD8þ T cells in the LCMV mouse model of acute and
chronic infection25,27,40. In line with this, we could correlate the
in vitro proliferative capacity of HCV epitope-speciﬁc CD8þ
T cells with TCF1 expression clearly suggesting that the TCF1
expressing subset contains the proliferative capacity within the
HCV epitope-speciﬁc CD8þ T-cell pool. This was further
supported by two in vivo observations. First, an increased
proliferative capacity of HCV epitope-speciﬁc CD8þ T cells
after cessation of chronic antigen stimulation occurred in parallel
with the increase of the TCF1þCD127þPD1þ HCV epitope-
speciﬁc T-cell subset. Second, TCF1þCD127þPD1þ HCV
epitope-speciﬁc CD8þ T cells robustly expanded in a patient
with viral relapse. This capacity of robust secondary expansion
represents a hallmark of CD8þ T-cell memory clearly supporting
the memory-like character of this HCV-speciﬁc CD8þ T-cell
subset. Consistently, a recent study in the mouse model of
chronic LCMV infection has shown that TCF1þ virus-speciﬁc
CD8þ T cells contain recall proliferative capacity after transfer in
acutely infected mice27. Hence, in humans and mice, antigen
persistence does not completely abrogate memory potential
regarding survival and proliferation characteristics of virus-
speciﬁc CD8þ T-cell pools. Of note, in human HCV infection,
this holds true after years of persistent antigen exposure at least in
the peripheral blood broadening the prospects for therapeutic
interventions.
Remarkably, memory-like TCF1þCD127þPD1þ HCV epi-
tope-speciﬁc CD8þ T cells present after DAA-mediated HCV
elimination do not fully resemble memory CD8þ T cells present
after spontaneous viral clearance. Although they share phenotypic
and molecular memory properties, like CD127, BCL2 and TCF1
expression, memory-like HCV-speciﬁc CD8þ T cells display a
higher expression of PD1 and Eomes indicative of T-cell
exhaustion. This ﬁts to the unique transcriptome of TCF1þ
LCMV-speciﬁc CD8þ T cells in chronically infected mice that
includes key factors of both signatures, T-cell memory and
exhaustion25,27. Furthermore, TCF1þ virus-speciﬁc CD8þ
T cells from chronic LCMV infection also maintained an
exhausted cytokine proﬁle after re-expansion in vivo27. Similarly,
memory-like HCV-speciﬁc CD8þ T cells also revealed impaired
cytokine production after DAA-mediated compared to
spontaneous antigen elimination. These cells therefore exhibit
phenotypic and functional characteristics of T-cell memory and
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peptides (10 mgml 1) for 5 h at 37 C and analysed for cytokine production (a,b). (a) Flow cytometric dot plots demonstrate stability of peptide/MHCI
tetramer staining (upper row) and IFNg and TNF production (lower row) of HCVepitope-speciﬁc CD8þ Tcells (red gate). (b) Cytokine production by HCV
epitope-speciﬁc CD8þ T cells of ﬁve patients with HCV infection (HCV; six HCV epitope-speciﬁc CD8þ T-cell responses), seven spontaneous resolvers
(SpR; ten HCV-epitope-speciﬁc CD8þ T-cell responses) and ﬁve FLU epitope-speciﬁc CD8þ T-cell responses (FLU, n¼ 5). (c–e) In vitro peptide-expanded
HCV epitope-speciﬁc CD8þ Tcells from HCV-infected patients (n¼ 9; 12 HCV epitope-speciﬁc CD8þ T-cell responses) or spontaneous resolvers (n¼ 8;
13 HCV epitope-speciﬁc CD8þ T-cell responses) were analysed for cytokine production after 5 h of peptide-speciﬁc re-stimulation. (c) Representative dot
plots showing cytokine production by in vitro HCVpeptide-expanded CD8þ Tcells after HCV peptide-speciﬁc re-stimulation (gated on bulk CD8þ Tcells).
Percentages of the respective quadrant are depicted. (d) Frequencies of IFNg- (left) and TNF-producing (right) in vitro peptide-expanded HCV epitope-
speciﬁc CD8þ Tcells are shown in the statistical graphs. (e) TNF production by IFNgþ in vitro peptide-expanded CD8þ Tcells in per cent. Bar charts show
the median value with interquartile range. Statistical signiﬁcance was assessed by Friedman test (HCV/DAA) and by unpaired KruskalWallis (HCV, SpR,
FLU). Multiple comparisons were performed with Dunn’s test. (*Po0.05.)
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exhaustion. Hence, memory-like HCV-speciﬁc CD8þ T cells and
TCF1þ LCMV-speciﬁc CD8þ T cells, both induced during
chronic infections, are clearly distinct from memory CD8þ T cells
generated in self-limiting infections suggesting a divergent T-cell
differentiation program. While conventional memory T cells are
equipped with extensive polyfunctionality to rapidly clear
re-infection, memory-like T cells established during chronic
infection might acquire a differentiation program that is adjusted
to the setting of persistent antigen allowing pathogen control
without immunopathology. This might have important
implications for vaccination strategies aiming to boost virus-
speciﬁc CD8þ T-cell responses during and after chronic antigen
stimulation.
Noteworthy, memory-like TCF1þ LCMV-speciﬁc CD8þ
T cells from chronically infected mice were able to control
LCMV infection after transfer in acutely infected mice27.
In humans, however, it is unclear whether memory-like
TCF1þCD127þPD1þ HCV-speciﬁc CD8þ T cells that persist
after DAA-mediated HCV clearance will be able to provide
protection against re-infection. In the chimpanzee model of
chronic HCV infection, a recent study has suggested that
exhausted HCV-speciﬁc CD8þ T-cell populations do not
functionally recover after DAA-mediated cure and are unable
to prevent virus persistence after re-infection41,42. In line with
this, multiple re-infections of DAA-treated patients have been
reported also questioning the presence of protective immune
memory after DAA clearance although the role of genotypes and
viral escape has not been addressed. Clearly, additional studies
are needed to address the protective potential of memory-like
HCV-speciﬁc CD8þ T cells. Our ﬁnding, however, of a
signiﬁcant re-expansion of this HCV-speciﬁc CD8þ T-cell
subset combined with a decent production of cytokines
indicates that protective immunity may be possible at least in a
subset of subjects.
Importantly, recall expansion of memory-like TCF1þCD127þ
PD1þ HCV-speciﬁc CD8þ T cells was accompanied by re-
occurrence of the TCF1-CD127-PD1hi subset after re-exposure to
persisting antigen suggesting a progenitor-progeny relationship of
these two subsets during chronic antigen recognition. The
CD127-PD1hi subset of HCV epitope-speciﬁc CD8þ T cells
highly expressed inhibitory receptors and CD39 and exhibited the
transcriptional TbetdimEomeshi signature that is characteristic for
terminal exhaustion6,12,15. Of note, it has previously been shown
that intrahepatic HCV-speciﬁc CD8þ T cells obtained from
chronically HCV-infected patients exclusively displayed a
TbetdimEomeshigh proﬁle15 raising the question of the CD127/
PD1 subset distribution at the site of HCV persistence.
Furthermore, CD127-PD1hi HCV epitope-speciﬁc CD8þ
T cells also expressed perforin, at least to some extent, and
increased levels of CD122 indicative of effector cell
differentiation34,43–45. Thus, the TCF1-CD127-PD1hi subset of
HCV-speciﬁc CD8þ T cells contains terminally exhausted
effector cells. Importantly, this terminally exhausted
TCF1-CD127-PD1hi effector subset was absent or disappeared
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infected patients (eleven HCV epitope-speciﬁc CD8þ T-cell responses) and four spontaneous resolvers (SpR; ﬁve HCV epitope-speciﬁc CD8þ T-cell
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14 of in vitro culture. (a) Representative dot plots of HCV epitope-speciﬁc CD8þ T cells determined by peptide/MHCI and CD8 staining at day 14 of
expansion at baseline (left plot) or at end of therapy (EOT; right plot), respectively. Quantiﬁcation of proliferative capacity of HCV epitope-speciﬁc CD8þ
Tcells derived from donors at baseline, at EOTand of SpR is depicted on the right. (b,c) Correlation analyses of the expansion factor with the abundance of
memory-like CD127þPD1þ (b) or TCF1þ (c) HCV epitope-speciﬁc CD8þ T cells at day 0 of the assay, respectively (grey: baseline; black: EOT; open
circles: SpR). Bar chart shows the median value with interquartile range. Statistical signiﬁcance was assessed with Wilcoxon test (HCV/DAA Baseline to
EOT), multiple comparisons with Kruskal–Wallis and Dunn’s test (SpR to cHCV Baseline/EOT). Pearson correlation in (b,c) was performed. (*Po0.05;
**Po0.01; ****Po0.0001.)
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from the HCV epitope-speciﬁc CD8þ T-cell population when
the corresponding viral epitope was removed either naturally in
the context of viral escape mutations or therapeutically by DAA
therapy. In sum, these results clearly indicate that terminal
exhaustion of HCV epitope-speciﬁc CD8þ T cells is linked to
ongoing antigen recognition and support previous ﬁndings from
the LCMV model showing antigen dependence of terminal
exhausted virus-speciﬁc CD8þ T cells46–48. The mechanism
responsible for the disappearance of the TCF1-CD127-PD1hi
HCV epitope-speciﬁc CD8þ T cells after antigen elimination is
not entirely clear but may be linked to a reduced lifespan of these
cells due to terminal differentiation. In agreement with this
hypothesis, we found low expression of the pro-survival molecule
BCL-2 that has been associated with a higher apoptosis rate of
virus-speciﬁc CD8þ T cells49. Furthermore, the lack of CD127
expression on the TCF1-CD127-PD1hi subset of HCV epitope-
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Figure 7 | Memory-like HCV-speciﬁc CD8þ T cells provide recall response after viral relapse. Longitudinal analyses of HCV epitope-speciﬁc
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þ T-cell populations at end of
therapy (EOT) and after viral relapse at FU12 and FU58 are shown. (c) CD127/PD1 subset distribution and relative expression of CD39 (d), Eomeshi (e) and
TCF1 (f) of NS31073-speciﬁc CD8
þ T cells were assessed at the indicated time-points (red: HCV epitope-speciﬁc CD8þ T cells; grey: corresponding
CD8þ T cells).
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speciﬁc CD8þ T cells abrogates sensing of IL-7 that is required
for antigen-independent survival of CD8þ T cells50. Persisting
antigen is therefore required to drive the generation of terminal
exhausted HCV-speciﬁc CD8þ T cells possibly arising from less
differentiated memory-like subsets similar to progenitor and
terminal subsets of virus-speciﬁc CD8þ T cells found in the
mouse model of chronic LCMV infection15,25–27. Since both
subsets are required to sustain the virus-speciﬁc CD8þ T-cell
response during antigen persistence in mice it is tempting to
speculate that a similar mechanism also exists in chronic human
infection.
In conclusion, we demonstrate for the ﬁrst time the emergence
of a less differentiated circulating memory-like subset of virus-
speciﬁc CD8þ T cells during antigen persistence in a relevant
chronic human infection that is maintained after cessation of
chronic antigen stimulation. Thus, our results give clinical
signiﬁcant insights into virus-speciﬁc CD8þ T-cell immunity
after elimination of chronic viral infection and have implications
for re-infection and therapeutic vaccination. In particular,
memory-like HCV epitope-speciﬁc CD8þ T cells contain the
proliferative potential and provide recall responses including
re-expansion of HCV epitope-speciﬁc CD8þ T cells and
re-occurrence of terminally exhausted subsets. Thus, this
memory-like subset appears to be central to maintain virus-
speciﬁc CD8þ T-cell responses during chronic infection and
after consequent DAA-mediated viral clearance rendering this
subset of virus-speciﬁc CD8þ T cells a promising target to boost
CD8þ T-cell responses in immune therapeutic interventions.
Methods
Study cohort. Patients were recruited at the Department of Medicine II of the
University Hospital Freiburg, Germany. 35 HLA-A*02 positive patients with
chronic HCV infection were included in this study. Twenty nine of these patients
could be followed through IFNa-free DAA therapy and ﬁve patients were treated
with IFNa-based regiments. All patients included in the study were infected with
HCV genotype 1a or 1b. Viral loads were determined as part of the clinical
diagnostics at the University Hospital Freiburg. In addition, 15 HLA-A*02 positive
patients who spontaneously resolved HCV infection (anti-HCV positive, HCV-
RNA negative) were included. Conﬁrmation of HLA-A*02 was performed by
antibody staining and four-digit HLA-typing by next generation sequencing.
Characteristics of the patient cohort can be found in Table 1.
Written informed consent was obtained in all cases and the study was conducted
according to federal guidelines, local ethics committee regulations (Albert-Ludwigs-
Universita¨t, Freiburg, Germany) and the Declaration of Helsinki (1975).
PBMC isolation. PBMCs were isolated from EDTA anticoagulated blood patient
samples through Pancoll (Pan-Biotech) density gradient centrfugation. For best
data comparability, all PBMC samples from one patient during therapy were frozen
and thawed simultaneously at the day of experiment. PBMCs were thawed in
complete medium (RPMI 1640 with 10% fetal bovine serum, 1% penicillin-
streptomycin and 1.5% 1M HEPES (all Thermo Fisher, Germany)) and incubated
for 15–30min at 37 C in complete medium containing 50Uml 1 benzonase
(Sigma, Germany) before processing.
Peptides and tetramers. Peptides of HLA-A*02-restricted HCV-derived
epitopes ((I) genotype 1a: NS31073, CINGVCWTV; NS31406, KLVALGINAV;
NS52594, ALYDVVTKL; (II) genotype 1b: NS31073, CVNGVCWTV; NS31406,
KLSGLGLNAV; NS52594, ALYDVVSTL), variant epitopes matching patient viral
sequences (Table 1), cytomegalovirus (CMV)-derived epitope pp65495,
NLVPMVATV, inﬂuenza virus (FLU)-derived epitope M158, GILGFVFTL, and
Epstein—Barr Virus (EBV)-derived epitope BMFL1280, GLCTLVAML, were
obtained from Genaxxon, Germany. Peptides were dissolved in dimethyl sulfoxide
(Sigma, Germany) at 20mgml 1 and diluted in complete medium to 1mgml 1
before usage. Major histocompatibility complex (MHC) class I epitope-speciﬁc
tetramers were generated by conjugation of biotinylated peptide-MHC class I
monomers (kind gift from David Price, Cardiff University) with PE- or APC-
conjugated streptavidin at a MHCI:Strepatividin molar ratio of 5:1.
Tetramer enrichment. Tetramer enrichment was performed as previously
described51. Brieﬂy, PBMCs were labelled with peptide/HLA-A*02 tetramers
coupled to either phycoerythrin (PE) or allophycocyanin (APC). Subsequent
enrichment was performed with anti-PE/APC beads applying MACS technology
(Miltenyi Biotec, Germany) according to the manufacturer’s protocol. Enriched
virus-speciﬁc CD8þ T cells were used for ﬂow cytometry or ex vivo stimulation
assays. To restrict analysis only to those cells that actually encountered antigen
before, CD45RAþCCR7þ or CD45RAþCD27þ naive virus-speciﬁc CD8þ
T cells were excluded (Supplementary Fig. 2). Samples were excluded when
o5 cells could be detected after peptide/HLA-A*02 tetramer-based enrichment.
Frequencies of virus-speciﬁc CD8þ T cells were calculated as described by
Alanio et al.51.
Multiparametric ﬂow cytometry. The following reagents were used for
multi-parametric ﬂow cytometry: anti-HLA-A*02 (BB7.2, 1:100), anti-HLA-B*27
(FD705-9E1E10, 1:100), anti-CD8 (SK1, 1:50), anti-Eomes (WD1928, 1:30),
anti-T-bet (4B10, 1:30), anti-CD14 (61D3, 1:100), anti-CD19 (HIB19, 1:100),
anti-TIGIT (MBSA43, 1:30) (eBioscience, Germany). Anti-CCR7 (G043H7, 1:30),
anti-CCR7 (G043H7, 1:30), anti-CD127 (A019D5, 1:30), anti-CD45RA (HI100,
1:200), anti-PD1 (EH12.2H7, 1:30), anti-TCF1 (C63D9, 1:30), anti-CD8 (HIT8a,
1:50), anti-2B4 (C1.7, 1:100), anti-CCR7 (150503, 1:30), anti-Rabbit IgG (Poly4064,
1:200), anti-CD45RA (HI100, 1:200), anti-Perforin (dG9, 1:50), anti-CD122 (TU27,
1:30), anti-IFN-g (4S.B3, 1:50) (BioLegend, UK). Anti-IFN-g (25723.11, 1:30),
anti-Bcl-2 (Bcl-2/100, 1:100), anti-TNF (MAb11, 1:50), anti-CD39 (TU66, 1:30),
anti-CD8 (RPA-T8, 1:100), anti-CD14 (MjP9, 1:100), anti-CD19 (SJ25C1, 1:100)
(BD Biosciences, Germany). Anti-TCF1 (C63D9, 1:100) (Cell signaling, Germany).
Fixable Viability Dyes (eFluor506 (1:100) or eFluor780 (1:5000), eBioscience,
Germany) and 7-AAD (1:30) (BD Biosciences, Germany) were used for live/dead
discrimination. FoxP3/Transcription Factor Staining Buffer Set (eBioscience,
Germany) was applied according to the manufacturer’s instructions to stain
for cytoplasmic and nuclear molecules. Cells were ﬁxed with paraformaldehyde
(2% PFA) before sample acquisition on a FACSCanto II or an LSRFortessa
(BD Biosciences, Germany).
T-cell expansion and calculation of expansion factor. Around 1–2 106 PBMCs
were stimulated with epitope-speciﬁc peptides (10mgml 1) and anti-CD28 (clone
CD28.2, 0.5 mgml 1, BD Biosciences, Germany) in 1ml complete medium and
incubated at 37 C for 14 days. At day 3, 7 and 10, culture was supplemented with
0.5ml of fresh medium including 20 IUml 1 rIL-2 (Miltenyi Biotec, Germany).
Tetramer and intracellular cytokine staining were performed at day 14. The
expansion index was calculated as follows: [A] The absolute number of virus-
speciﬁc CD8þ T cells added at day 0 of in vitro expansion was calculated based on
peptide/MHCI tetramer enrichments (see above). [B] At day 14 of in vitro
expansion, the absolute number of expanded virus-speciﬁc CD8þ T cells was
determined based on direct FACS analyses. The expansion index was then calcu-
lated as (([B]/[A])þ 1), allowing subsequent logarithmic calculation despite zero
values, resulting in the expansion factor¼ log(expansion index).
Cytokine production. Cytokine production of virus-speciﬁc CD8þ T cells after 14
days of in vitro expansion or directly ex vivo after peptide/MHCI tetramer
enrichment of virus-speciﬁc CD8þ T cells was induced by re-stimulating cells with
epitope-speciﬁc peptides (10 mgml 1) in the presence of brefeldin A
(GolgiPlug; 0.5 ml ml 1) and monensin (GolgiStop; 0.325 ml ml 1) (BD
Biosciences, Germany) for 5 h at 37 C. Stimulation with phorbol 12-myristate
13-acetate (PMA; 50 ngml 1, Sigma, Germany) and Ionomycin (1 mgml 1,
Sigma, Germany) was performed as positive control. Subsequently, cells were
stained as described above.
Viral sequencing. RNA was extracted from sera using the QIAmp viral RNA
minikit (Qiagen, Germany) followed by reverse transcription (RT; SuperScript III
First-Strand Kit, Invitrogen, Germany) and DNA ampliﬁcation by nested PCR
(both PCRs via GoTaq G2 Flexi DNA Polymerase Kit, Promega, Germany)
according to manufacturers’ protocols. Speciﬁc primers for HCV genotype 1a and
1b can be found in Supplementary Table 3.
T-cell cross-reactivity with viral sequence variations. Epitope-speciﬁc T-cell
lines were generated from PBMCs by stimulation with viral peptides (wildtype
sequences) and expansion for 14 days as described above. On day 14, T-cell lines
were tested for IFNg production upon peptide-speciﬁc stimulation as described
above. For stimulation, HLA-A*02:01 positive EBV-transformed B-LCLs were
loaded with peptides ((a) wildtype peptide; (b) viral sequence variation peptide;
(10 mgml 1)) overnight, then washed extensively and ﬁnally co-cultured with
T-cell lines at an E:T ratio of 1:1. For production of EBV-transformed B-LCLs
from HLA-A*02 positive subjects, supernatant from the EBV-producing B95-8
marmoset lymphoblastoid cell line was incubated with donor PBMCs of patients
with known HLA-A*02 genotype followed by cyclosporine treatment52.
Cross-recognition deﬁnitions were based on Cox et al.53. Brieﬂy, loss of
recognition was deﬁned as at least 20-fold reduction in IFNg production upon
variant peptide stimulation compared to wildtype peptide stimulation; 2-fold and
less reduction in IFNg production was deﬁned as cross-recognition.
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Statistics. Flow cytometry data were analysed using FlowJo software version 9 and
10 (Treestar, USA). During data analysis by FlowJo, no further sub-gate analysis
was performed when o5 cells were detected. Statistical analysis was performed
with GraphPad 6 software (GraphPad Prism Software Inc., USA). Bar charts show
median values with interquartile range. Two-tailed tests were applied to a sig-
niﬁcance level of 95%. Statistical tests used are indicated in the ﬁgure legends.
When patients did not appear to one single study time point for unknown reasons,
missing at random (MAR) was assumed for statistical analysis. Paired analysis of
these data sets was then performed by applying the lastly collected value to the
missing time point. (*Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.)
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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